

Rating	Buy
Price target	220.00 EUR (prior: 200,00 EUR)
Potential	29%
Share data	
Share price (last closing price in EUR)	170.90
Number of shares (in m)	10.2
Market cap. (in EUR m)	1,739.1
Trading vol. (Ø 3 months; in k shares)	38.3
Enterprise Value (in EUR m)	1,801.8
Ticker	ACT
Guidance	
Sales (in EUR m)	ca. 600
EBITDA (in EUR m)	ca. 126

Share price (EUR)



Shareholder	
Freefloat	73.6%
four two na GmbH	10.1%
Staluna Trade a.s.	9.9%
Löw SE	6.4%
-	-

Calendar	
H1 report	July 30, 2026
Q3 report	October 29, 2026
-	-

Changes in estimates			
	2026e	2027e	2028e
Sales (old)	612.7	696.0	814.0
Δ	-	-	-
EBIT (old)	94.1	109.8	137.3
Δ	-	-	-
EPS (old)	6.27	7.27	9.46
Δ	-	-	-

Analyst	
Patrick Speck, CESGA	
+49 40 41111 37 70	
p.speck@montega.de	

Publication	
Comment	July 10, 2026

US Site Confirmed – Share Price Weakness Offers Upside

Alzchem recently announced that it has now made the location decision for establishing its first production facility in the United States.

US production in South Carolina: The Group's first US plant will be built in Bushy Park, South Carolina, to supply the US market with the defense product nitroguanidine (NQ) under a contract with the US Department of Defense. Intermediate products will continue to be manufactured at the company's German sites. Following the successful completion of the site selection process, the focus will now shift to advancing the Front-End Engineering and Design (FEED) process, refining the technical planning, obtaining regulatory approvals, and finalizing the contract negotiations with the US government. In our view, the latter is likely to focus primarily on the exact production volume. Based on the planned investment of approximately USD 150m, which is supported by funding commitments from US authorities, we believe management is targeting a production scale for the US facility comparable to that of the new NQ plant currently under construction in Germany. Construction of the US facility is scheduled to begin during 2027, with production expected to commence in 2029. As a result, Alzchem now has three highly visible growth drivers supporting profitable expansion over the coming years:

- **Additional NQ production in Germany:** Commissioning of the new NQ production capacity in Germany is expected during H2 2026 and should contribute annual revenue in the high double-digit EUR million range from 2027 onwards.
- **Additional creatine production in Germany:** Beginning in H2 2027 and from the following year, 2028, the new creatine production facility in Germany (see Comment dated 09/12/2025) is expected to generate revenue in the low triple-digit EUR million range.
- **New NQ production in the US:** From 2029/2030 onwards, NQ sales in the US are also expected to contribute annual revenue in the high double-digit EUR million range.

All three expansion projects relate to the high-margin Specialty segment, which we expect to generate EBITDA margins of more than 28% (MONE). The Specialty segment's share of Group revenue should gradually increase to around 80% by 2030 (2025: 67.4%), driving total revenue to approximately EUR 1bn by 2030/2031 (CAGR 2026–2031: 11.1%).

Solid Q2 expected: For the recently completed Q2 2026 (earnings call on 30 July via AIRTIME), we expect only modest growth given the already highly utilized production capacity (MONE revenue: +2.9% yoy to EUR 147.0m), another disproportionate increase in earnings (MONE EBITDA: +10.0% yoy to EUR 32.0m), and confirmation of the company's guidance (revenue of approximately EUR 600m; EBITDA of approximately EUR 126m).

Conclusion: The implementation of the US expansion plans is now certain and should significantly strengthen Alzchem's market position in its key product NQ as well as in the strategically important US defense sector. Although we had already incorporated the main effects of the capacity expansion into our valuation model, we are further increasing our long-term margin assumptions (terminal value margin: +190bps to 23.0%). The earnings multiples, which appear demanding at first glance (2026e EV/EBITDA: 14.1x vs. peer median: 10.2x), should become noticeably less demanding over the coming years. We reiterate our Buy recommendation and raise our target price to EUR 220.00 (previously: EUR 200.00).

FYend: 31.12.	2024	2025	2026e	2027e	2028e
Sales	554.2	562.1	612.7	696.0	814.0
Growth yoy	2.5%	1.4%	9.0%	13.6%	17.0%
EBITDA	105.3	116.5	127.4	151.7	184.8
EBIT	79.0	89.8	94.1	109.8	137.3
Net income	54.1	63.5	63.8	74.0	96.3
Gross profit margin	65.1%	67.6%	66.5%	64.5%	64.8%
EBITDA margin	19.0%	20.7%	20.8%	21.8%	22.7%
EBIT margin	14.2%	16.0%	15.4%	15.8%	16.9%
Net Debt	88.2	60.8	68.6	122.1	110.3
Net Debt/EBITDA	0.8	0.5	0.5	0.8	0.6
ROCE	25.9%	29.2%	27.3%	26.0%	27.2%
EPS	5.31	6.28	6.27	7.27	9.46
FCF per share	6.10	3.85	1.32	-3.11	3.65
Dividend	1.80	2.10	2.14	2.50	3.25
Dividend yield	1.1%	1.2%	1.3%	1.5%	1.9%
EV/Sales	3.3	3.2	2.9	2.6	2.2
EV/EBITDA	17.1	15.5	14.1	11.9	9.8
EV/EBIT	22.8	20.1	19.2	16.4	13.1
PER	32.2	27.2	27.3	23.5	18.1
P/B	8.5	6.8	5.8	4.9	4.1

Source: Company data, Montega, Capital IQ

Figures in EUR m, EPS in EUR, Price: 170.90 EUR

Company Background

Alzchem Group AG is a vertically integrated specialty chemicals provider with a leading market position in selected and diversified niche markets such as Health & Pharma, Human & Animal Nutrition, Renewable Energies, Agriculture and Farming, Metallurgy, Fine Chemistry, as well as Automotive & Defense. Additionally, as a contract manufacturer (Custom Manufacturing), multipurpose plants for customer-specific solutions are operated. Alzchem's main chemical products are based on technological leadership along the calcium carbide/calcium cyanamide chain (known as the NCN chain), which are organic nitrogen-carbon-nitrogen bonds that branch out into a product tree with over 900 registered product brands ranging from basic chemicals to complex specialty chemicals. The roots of the entire NCN chain always lie in the commodities lime, coal (coke), and electricity, which are processed and globally marketed in a production network at four historically developed sites in the East Bavarian chemical triangle (Trostberg, Schalchen, Hart, Waldkraiburg) as well as in Sundsvall (Sweden).

Key Facts


Sector	Specialty chemicals
Ticker	ACT
Employees	1,765
Sales	562.1 m EUR
EBITDA	116.5 m EUR
EBITDA margin	20.7%
Business model	Development, production and distribution of high-quality and innovative specialty and basic chemicals for a wide range of solutions to global challenges such as climate change, nutrition, health and safety.
Core competence	Vertically integrated production (four plants in Germany, one in Sweden) based on the calcium carbide/calcium cyanamide chain (so-called NCN chain) with a strategic focus on growth in the Specialty Chemicals business segment.
Customer structure	Regionally and sectorally broadly diversified customer base and long-standing relationships with key customers; top 10 customers account for approx. 33% of sales revenue

Source: Company, Montega; Status: FY 2025

Key events in the company's history


The roots of the Alzchem Group and its predecessor companies date back to the late 19th and early 20th centuries, when chemists first succeeded in binding nitrogen from the air with earth alkali carbides (nitriding), and a few years later the benefits of calcium cyanamide as a fertilizer were recognized. In 1908, the entrepreneurial starting signal was finally given with the founding of the Bayerische Stickstoffwerke AG. The subsequent construction of the calcium cyanamide plant in Trostberg, the carbide plant in Schalchen, the factory channel, and two hydroelectric power plants at the two locations formed the nucleus for today's production network in southeastern Bavaria.





Organizational and segment structure

The business activities of Alzchem are divided into three reporting segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding. In the **Specialty Chemicals** segment, which is the most economically significant (revenue contribution: 67%; EBITDA contribution: 94%), the company focuses on the production and distribution of high-quality chemical products for numerous processing industries and end consumers. The **Basics & Intermediates** segment (revenue contribution: 28%; EBITDA contribution: 5%) produces chemical precursors and intermediates as a basis for refining in the group's own specialty chemicals as well as for direct sale to third parties. The smallest segment, **Other & Holding**, encompasses other activities, which mainly include services around the Trostberg and Hart chemical parks.




Source: Company

The holding functions for the Alzchem group are carried out by the **Alzchem Group AG** as the parent company. The consolidation scope also includes various production and distribution companies in Germany, Sweden, the UK, USA, and China, all of which are fully consolidated.

Markets and products

The most important sales regions of the company are the home market Germany (sales share 2025: 29%) and the rest of the EU (31%). These are followed by overseas markets in North America (18%) and Asia (7%). The rest of the world accounts for about 10%. The main end markets also show diversity: Agriculture is, in our opinion, the largest customer sector with a revenue share of around 16%.



Source: Company

The company's entire product portfolio includes more than 900 registered brands. One of the most important is, in our opinion, the premium brand Creapure for high-purity creatine monohydrate, with which Alzchem, as the only Western manufacturer, holds a leading market position in the sports nutrition industry. The creatine family includes LIVADUR, which is Alzchem's first own end-consumer product. Other flagship brands are the feed additive Creamino and the dual-use product Nitroguanidin, which as a very stable energetic compound is also suitable for defense applications.

Extract from Alzchem's product catalogue

Brand	Product description	End markets
 Creapure®	Premium brand for creatine monohydrate as a dietary supplement in sports nutrition	Human Nutrition
 CREAMINO®	Feed additive for the supply of creatine in livestock farming	Animal Nutrition
 Dormex®	Plant growth regulator for wine and fruit cultivation	Agriculture
 Perlka®	Special fertiliser with pearled calcium cyanamide	Agriculture
 CaD	Calcium carbide-based metallurgical additive for hot metal desulphurisation	Metallurgy
 NITRALZ®	Diverse and high-quality aliphatic and aromatic nitriles as raw materials for pharmaceuticals, pigments, agrochemicals and biocides	Pharmacy, Agriculture, Basic chemicals
 Eminex®	Additive containing calcium cyanamide to reduce methane and CO2 emissions from liquid manure in livestock farming	Agriculture
 Creavitalis®	Creatine monohydrate as a fine, flavourless powder for the food and pharmaceutical industries (e.g. meat alternatives, milk substitutes)	Human Nutrition
Nitroguanidin	Dual-use product (propellant charge) for civil and defence applications (including airbags, belt tensioners, ammunition) and agricultural chemistry	Automotive, Defense, Agriculture
 Silzot®	Silicon nitride powder for high-performance ceramics in electronic circuit carriers	Electronics, Automotive
 DYHARD®	Hardeners and accelerators in powder, paste and liquid form for epoxy resins in composite and lightweight construction	Renewable energies, Automotive, Aviation
 Bioselect®	High-purity form of guanidine hydrochloride salts and guanidine thiocyanate for cancer diagnostics and corona test kits	Pharmacy
 LIVADUR®	Dietary supplement with creatine in premium quality for active athletes	Human Nutrition

Source: Company, Montega

Management

The Alzchem Group is currently led by a four-member executive board team.



Andreas Niedermaier (CEO) was born in Tittmoning in 1969. After studying industrial engineering in Rosenheim, he began his career as Consultant for Cost Calculators and Controllers at Kettner Maschinenbau GmbH. He worked as Controller for Vinnolit GmbH & Co. KG in Gendorf and Burghausen from 1997 to 1999, where he was responsible for production facility controlling. Andreas Niedermaier has been with Alzchem and its predecessors since 1999. He has served as Managing Director of Alzchem Trostberg GmbH since 2010 and also as a Member of the Management Board (until 06/2019 CFO and from 07/2019 CEO) of Alzchem Group AG since Alzchem Trostberg GmbH was incorporated into the listed Group in October 2017.



Andreas Lösler (CFO) was born in Wernigerode in 1975. After completing his apprenticeship as a tax assistant, he studied business administration with a focus on accounting and finance at the Universities of Marburg and Hamburg and at the Copenhagen Business School. He began his professional career at the consulting firm FAS AG in Stuttgart, which specializes in international accounting. His career then took him to a listed investment company, where he was responsible for the integration of newly acquired companies into the reporting system. Since 2007, Mr. Lösler has been the founder and managing director of DEOS Advisory GmbH, which advises companies on all aspects of capital market-oriented accounting and reporting. He has also been working in an advisory capacity for the Alzchem Group since 2012 and supported the company, in particular with the IPO in 2017. Since June 2022, Mr. Lösler has been interim Head of Controlling & Accounting at Alzchem Group and has been CFO of Alzchem Group AG since January 1, 2024.



Dr. Jürgen Sans (COO) was born in Mosbach in 1968. He studied chemistry at the University of Karlsruhe (TH), followed by a doctorate in chemical engineering at the Engler-Bunte Institute. He began his professional career as a laboratory manager in the research department at SKW, where he was responsible for nitriles and cyanuric chloride. In 2002, following the merger with Degussa-Hüls, he moved to the Marketing & Sales department, where he was responsible for marketing various products in different markets. After 2006, he was responsible for the acquisition of new products and the sale of established products for multi-purpose plants in Trostberg. In 2011, Dr. Sans took over as head of the Process Development department, where he was responsible for Six Sigma, chemical safety & scale-up, gas phase reactions, and process optimization. Since 2016, he has been responsible for innovation management, including the departments of analytics, research and development, application technology, and GxP-QS. Dr. Jürgen Sans has been COO of Alzchem Group AG since January 1, 2026.




Martina Spitzer (CSO), born in Trostberg in 1983, has been working for the Alzchem Group since 1999. In 2020, she was appointed head of Alzchem's entire chemical sales division, before she shifted her focus to strategic corporate development and ESG in 2022 after around 15 years in sales. In this role, she played a decisive role in the introduction of the sustainability division, the optimisation of central business processes and the implementation of forward-looking projects. Martina Spitzer has been CSO of Alzchem Group AG since 1 January 2025.

Shareholder structure

Since October 5, 2017, the shares of Alzchem Group AG have been listed in the Prime Standard of the Frankfurt Stock Exchange. Apart from the IPO in 2017, no capital increases have been carried out since then. The subscribed capital amounts to approximately 101.8m EUR and is divided into 10,176,335 no-par value bearer shares with a notional share in the share capital of EUR 10.00 each. On October 2, 2024, the share was included in the SDAX index.

The largest shareholder is currently the financial investor four two na GmbH with 10.1%, ahead of the investment company Löw SE (6.4%) and Staluna Trade a.s. (9.9%). The free float amounts to approximately 73.6%.



Source: Company

DCF Model

Figures in EUR m

	2026e	2027e	2028e	2029e	2030e	2031e	2032e	Terminal Value
Sales	612.7	696.0	814.0	895.9	976.5	1,035.1	1,086.9	1,108.6
Change yoy	9.0%	13.6%	17.0%	10.1%	9.0%	6.0%	5.0%	2.0%
EBIT	94.1	109.8	137.3	159.2	195.3	232.9	250.0	255.0
EBIT margin	15.4%	15.8%	16.9%	17.8%	20.0%	22.5%	23.0%	23.0%
NOPAT	68.0	77.7	100.8	119.1	140.6	167.7	180.0	183.6
Depreciation	33.4	42.0	47.5	52.2	53.7	56.9	57.6	43.2
in % of Sales	5.5%	6.0%	5.8%	5.8%	5.5%	5.5%	5.3%	3.9%
Change in Liquidity from								
- Working Capital	31.0	-67.0	-56.0	-36.0	-78.7	-15.2	-13.5	-1.2
- Capex	-114.9	-80.9	-50.9	-50.9	-51.8	-49.7	-48.9	-44.3
Capex in % of Sales	18.8%	11.6%	6.3%	5.7%	5.3%	4.8%	4.5%	4.0%
Other								
Free Cash Flow (WACC model)	17.5	-28.2	41.4	84.4	107.5	167.6	182.2	184.2
WACC	7.7%	7.7%	7.7%	7.7%	7.7%	7.7%	7.7%	7.7%
Present value	17.3	-25.9	35.2	66.7	78.9	114.2	115.3	1,897.6
Total present value	17.3	-8.6	26.6	93.3	172.2	286.5	401.8	2,299.4

Valuation

Total present value (Tpv)	2,299.4
Terminal Value	1,897.6
Share of TV on Tpv	83%
Liabilities	134.4
Liquidity	71.7
Equity value	2,236.7

Number of shares (mln)	10.2
Value per share (EUR)	219.8
+Upside / -Downside	29%
Share price	170.90

Model parameter

Debt ratio	35.0%
Costs of Debt	4.0%
Market return	9.0%
Risk free rate	2.5%

Beta	1.2
WACC	7.7%
Terminal Growth	2.0%

Growth: sales and margin

Short term sales growth	2026-2029	13.5%
Mid term sales growth	2026-2032	10.0%
Long term sales growth	from 2033	2.0%
Short term EBIT margin	2026-2029	16.4%
Mid term EBIT margin	2026-2032	18.8%
Long term EBIT margin	from 2033	23.0%

Sensitivity Value per Share (EUR)

Terminal Growth

WACC	1.25%	1.75%	2.00%	2.25%	2.75%
8.20%	180.43	191.89	198.32	205.28	221.13
7.95%	188.93	201.51	208.59	216.29	233.92
7.70%	198.12	211.96	219.79	228.34	248.03
7.45%	208.08	223.36	232.05	241.58	263.68
7.20%	218.90	235.83	245.52	256.19	281.11

Sensitivity Value per Share (EUR)

EBIT-margin from 2033e

WACC	22.50%	22.75%	23.00%	23.25%	23.50%
8.20%	194.72	196.52	198.32	200.11	201.91
7.95%	204.78	206.69	208.59	210.50	212.40
7.70%	215.75	217.77	219.79	221.81	223.83
7.45%	227.76	229.90	232.05	234.20	236.35
7.20%	240.94	243.23	245.52	247.81	250.10

Source: Montega

P&L (in EUR m) Alzchem Group AG	2023	2024	2025	2026e	2027e	2028e
Sales	540.6	554.2	562.1	612.7	696.0	814.0
Increase / decrease in inventory	-3.8	-5.3	16.0	0.0	0.0	0.0
Own work capitalised	4.9	7.5	0.0	9.2	4.2	4.9
Total sales	541.7	556.4	578.2	621.9	700.2	818.9
Material Expenses	225.1	195.7	198.3	214.4	251.3	291.4
Gross profit	316.6	360.7	379.9	407.4	448.9	527.5
Personnel expenses	145.6	160.5	173.6	177.7	183.0	210.8
Other operating expenses	98.5	104.8	113.1	118.9	128.1	148.1
Other operating income	9.0	9.8	23.3	16.5	13.9	16.3
EBITDA	81.4	105.3	116.5	127.4	151.7	184.8
Depreciation on fixed assets	25.2	25.4	26.6	32.5	41.1	46.4
EBITA	56.2	79.9	89.8	95.0	110.7	138.4
Amortisation of intangible assets	0.7	1.0	0.0	0.9	0.9	1.1
Impairment charges and Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	55.5	79.0	89.8	94.1	109.8	137.3
Financial result	-7.3	-3.6	-1.9	-5.5	-4.9	-5.7
Result from ordinary operations	48.2	75.3	87.9	88.5	104.9	131.6
Extraordinary result	0.0	0.0	0.0	0.0	0.0	0.0
EBT	48.2	75.3	87.9	88.5	104.9	131.6
Taxes	13.4	21.1	24.3	24.5	30.6	35.0
Net Profit of continued operations	34.8	54.2	63.6	64.0	74.3	96.6
Net Profit of discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0
Net profit before minorities	34.8	54.2	63.6	64.0	74.3	96.6
Minority interests	0.2	0.2	0.2	0.2	0.3	0.3
Net profit	34.6	54.1	63.5	63.8	74.0	96.3

Source: Company (reported results), Montega (forecast)

P&L (in % of Sales) Alzchem Group AG	2023	2024	2025	2026e	2027e	2028e
Sales	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Increase / decrease in inventory	-0.7%	-1.0%	2.9%	0.0%	0.0%	0.0%
Own work capitalised	0.9%	1.3%	0.0%	1.5%	0.6%	0.6%
Total sales	100.2%	100.4%	102.9%	101.5%	100.6%	100.6%
Material Expenses	41.6%	35.3%	35.3%	35.0%	36.1%	35.8%
Gross profit	58.6%	65.1%	67.6%	66.5%	64.5%	64.8%
Personnel expenses	26.9%	29.0%	30.9%	29.0%	26.3%	25.9%
Other operating expenses	18.2%	18.9%	20.1%	19.4%	18.4%	18.2%
Other operating income	1.7%	1.8%	4.2%	2.7%	2.0%	2.0%
EBITDA	15.1%	19.0%	20.7%	20.8%	21.8%	22.7%
Depreciation on fixed assets	4.7%	4.6%	4.7%	5.3%	5.9%	5.7%
EBITA	10.4%	14.4%	16.0%	15.5%	15.9%	17.0%
Amortisation of intangible assets	0.1%	0.2%	0.0%	0.2%	0.1%	0.1%
Impairment charges and Amortisation of goodwill	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
EBIT	10.3%	14.2%	16.0%	15.4%	15.8%	16.9%
Financial result	-1.3%	-0.7%	-0.3%	-0.9%	-0.7%	-0.7%
Result from ordinary operations	8.9%	13.6%	15.6%	14.5%	15.1%	16.2%
Extraordinary result	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
EBT	8.9%	13.6%	15.6%	14.5%	15.1%	16.2%
Taxes	2.5%	3.8%	4.3%	4.0%	4.4%	4.3%
Net Profit of continued operations	6.4%	9.8%	11.3%	10.5%	10.7%	11.9%
Net Profit of discontinued operations	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net profit before minorities	6.4%	9.8%	11.3%	10.5%	10.7%	11.9%
Minority interests	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net profit	6.4%	9.8%	11.3%	10.4%	10.6%	11.8%

Source: Company (reported results), Montega (forecast)

Balance sheet (in EUR m) Alzchem Group AG	2023	2024	2025	2026e	2027e	2028e
ASSETS						
Intangible assets	3.7	3.7	3.5	2.6	1.7	0.6
Property, plant & equipment	177.3	193.0	277.0	359.4	399.2	403.7
Financial assets	0.0	0.0	0.0	0.0	0.0	0.0
Fixed assets	181.0	196.7	280.5	362.0	401.0	404.4
Inventories	107.5	101.2	116.0	92.8	126.5	150.7
Accounts receivable	75.2	78.9	73.4	67.1	85.8	100.4
Liquid assets	11.9	61.5	71.7	88.8	83.3	95.1
Other assets	49.2	45.5	76.0	76.0	76.0	76.0
Current assets	243.7	287.2	337.2	324.7	371.7	422.2
Total assets	424.7	483.8	617.7	686.7	772.6	826.6
LIABILITIES AND SHAREHOLDERS' EQUITY						
Shareholders' equity	161.6	205.5	256.3	298.9	351.4	422.7
Minority Interest	1.9	1.9	1.9	1.9	1.9	1.9
Provisions	123.5	122.6	114.4	114.4	114.4	114.4
Financial liabilities	62.5	52.8	44.2	69.2	117.2	117.2
Accounts payable	31.6	37.4	51.7	53.7	59.1	66.9
Other liabilities	43.6	63.5	149.1	148.5	128.5	103.5
Liabilities	261.1	276.4	359.4	385.8	419.2	402.0
Total liabilities and shareholders' equity	424.7	483.8	617.7	686.7	772.6	826.6

Source: Company (reported results), Montega (forecast)

Balance sheet (in %) Alzchem Group AG	2023	2024	2025	2026e	2027e	2028e
ASSETS						
Intangible assets	0.9%	0.8%	0.6%	0.4%	0.2%	0.1%
Property, plant & equipment	41.7%	39.9%	44.8%	52.3%	51.7%	48.8%
Financial assets	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Fixed assets	42.6%	40.6%	45.4%	52.7%	51.9%	48.9%
Inventories	25.3%	20.9%	18.8%	13.5%	16.4%	18.2%
Accounts receivable	17.7%	16.3%	11.9%	9.8%	11.1%	12.1%
Liquid assets	2.8%	12.7%	11.6%	12.9%	10.8%	11.5%
Other assets	11.6%	9.4%	12.3%	11.1%	9.8%	9.2%
Current assets	57.4%	59.4%	54.6%	47.3%	48.1%	51.1%
Total Assets	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
LIABILITIES AND SHAREHOLDERS' EQUITY						
Shareholders' equity	38.1%	42.5%	41.5%	43.5%	45.5%	51.1%
Minority Interest	0.5%	0.4%	0.3%	0.3%	0.3%	0.2%
Provisions	29.1%	25.3%	18.5%	16.7%	14.8%	13.8%
Financial liabilities	14.7%	10.9%	7.2%	10.1%	15.2%	14.2%
Accounts payable	7.4%	7.7%	8.4%	7.8%	7.6%	8.1%
Other liabilities	10.3%	13.1%	24.1%	21.6%	16.6%	12.5%
Total Liabilities	61.5%	57.1%	58.2%	56.2%	54.3%	48.6%
Total Liabilities and Shareholders' Equity	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Source: Company (reported results), Montega (forecast)

Statement of cash flows (in EUR m) Alzchem Group AG	2023	2024	2025	2026e	2027e	2028e
Net income	34.8	54.2	63.6	64.0	74.3	96.6
Depreciation of fixed assets	25.2	25.4	26.6	32.5	41.1	46.4
Amortisation of intangible assets	0.7	1.0	0.0	0.9	0.9	1.1
Increase/decrease in long-term provisions	10.2	-3.4	-8.7	0.0	0.0	0.0
Other non-cash related payments	12.2	33.6	-40.1	0.0	0.0	0.0
Cash flow	83.1	110.8	41.5	97.4	116.2	144.1
Increase / decrease in working capital	-10.4	-5.6	95.5	31.0	-67.0	-56.0
Cash flow from operating activities	72.7	105.1	137.0	128.4	49.2	88.1
CAPEX	-20.6	-43.1	-97.8	-114.9	-80.9	-50.9
Other	0.0	12.1	0.9	0.0	0.0	0.0
Cash flow from investing activities	-20.5	-31.0	-96.9	-114.9	-80.9	-50.9
Dividends paid	-10.6	-12.2	-18.2	-21.4	-21.8	-25.4
Change in financial liabilities	-37.7	-9.7	-8.6	25.0	48.0	0.0
Other	-0.8	-2.8	-2.6	0.0	0.0	0.0
Cash flow from financing activities	-49.2	-24.7	-29.4	3.6	26.2	-25.4
Effects of exchange rate changes on cash	-0.3	0.2	-0.6	0.0	0.0	0.0
Change in liquid funds	3.0	49.5	10.8	17.1	-5.5	11.7
Liquid assets at end of period	11.9	61.5	71.7	88.8	83.3	95.1

Source: Company (reported results), Montega (forecast)

Key figures Alzchem Group AG	2023	2024	2025	2026e	2027e	2028e
Earnings margins						
Gross margin (%)	58.6%	65.1%	67.6%	66.5%	64.5%	64.8%
EBITDA margin (%)	15.1%	19.0%	20.7%	20.8%	21.8%	22.7%
EBIT margin (%)	10.3%	14.2%	16.0%	15.4%	15.8%	16.9%
EBT margin (%)	8.9%	13.6%	15.6%	14.5%	15.1%	16.2%
Net income margin (%)	6.4%	9.8%	11.3%	10.5%	10.7%	11.9%
Return on capital						
ROCE (%)	17.3%	25.9%	29.2%	27.3%	26.0%	27.2%
ROE (%)	23.7%	33.1%	30.6%	24.7%	24.6%	27.3%
ROA (%)	8.2%	11.2%	10.3%	9.3%	9.6%	11.6%
Solvency						
YE net debt (in EUR)	150.9	88.2	60.8	68.6	122.1	110.3
Net debt / EBITDA	1.9	0.8	0.5	0.5	0.8	0.6
Net gearing (Net debt/equity)	0.9	0.4	0.2	0.2	0.3	0.3
Cash Flow						
Free cash flow (EUR m)	52.1	62.0	39.2	13.5	-31.7	37.2
Capex / sales (%)	3.8%	7.8%	17.4%	18.8%	11.6%	6.3%
Working capital / sales (%)	27.0%	26.5%	16.9%	5.2%	7.1%	13.7%
Valuation						
EV/Sales	3.3	3.3	3.2	2.9	2.6	2.2
EV/EBITDA	22.1	17.1	15.5	14.1	11.9	9.8
EV/EBIT	32.5	22.8	20.1	19.2	16.4	13.1
EV/FCF	34.6	29.0	45.9	133.6	-	48.5
PE	50.3	32.2	27.2	27.3	23.5	18.1
P/B	10.8	8.5	6.8	5.8	4.9	4.1
Dividend yield	0.7%	1.1%	1.2%	1.3%	1.5%	1.9%

Source: Company (reported results), Montega (forecast)

DISCLAIMER

General Information

This document neither constitutes an offer nor an invitation to buy or sell securities, other financial instruments or any other investment instruments. It is intended for information purposes only. This document is not tailored to the specific investment objectives, financial situation or particular needs of the recipient and therefore does not constitute personal investment advice. Recipients should make their own investment decisions based on their individual investment objectives, financial situation and needs, and taking into account all available information on the financial instrument, in particular sales prospectuses or comparable information sources, and, where appropriate, with the support of an independent financial adviser.

The information, statements, assessments and forecasts contained in this document reflect the personal views of the author as of the date of publication. Such opinions are subject to change at any time without notice, and Montega is under no obligation to supplement, amend or update this document or to otherwise inform the recipient thereof. To the extent that this document contains information on past performance, recipients should note that past performance is not a reliable indicator of future performance.

Montega AG is the principal shareholder of Montega Markets GmbH. Montega Markets GmbH provides investment banking and corporate finance services to issuers. In this context, research publications of Montega AG may be used in a supporting capacity within such mandates. This may give rise to potential conflicts of interest. Existing or potential conflicts of interest are disclosed transparently in the section "Disclosure" of this publication in accordance with applicable legal requirements.

Disclaimer of Liability

This document and the statements contained herein are based on information and sources which we consider to be reliable. However, we do not provide any representation or warranty as to the accuracy or completeness of the information, statements, assessments or forecasts contained in this document. Any incomplete or inaccurate information, statements, assessments or forecasts shall not give rise to any liability on the part of Montega, its shareholders, analysts or the institutions commissioning them for any damages or other disadvantages of whatever nature arising from the distribution or use of this document, which are hereby excluded.

In particular, Montega assumes no liability for statements, assumptions, projections or other information relating to the analysed companies, their affiliated entities, business strategies, market, competitive or macroeconomic conditions, or regulatory and legal frameworks.

Restrictions on Distribution and Dissemination Outside Germany/EU

Any forwarding or distribution of this report to third parties is only permitted with the prior consent of Montega. All copyrights and usage rights in this document remain with Montega. All applicable capital markets regulations governing the preparation, content and distribution of research in the respective national jurisdictions must be observed and complied with by both the provider and the recipient.

Distribution in the United Kingdom: This document is directed only at persons who are authorised or exempt persons within the meaning of the Financial Services Act 1986 or any order made thereunder, or at persons described in Article 11 (3) of the Financial Services Act 1986 (Investment Advertisements) (Exemptions) Order 1996 (as amended), and it is not intended that it be distributed, directly or indirectly, to any other group of persons.

Restricted jurisdictions: Neither this document nor any copy thereof may be taken into, transmitted or distributed in or into the United States of America, Canada, Japan or any of their territories or possessions.

Competent Supervisory Authority

Montega AG (Schauenburgerstraße 10, 20095 Hamburg) is supervised by the Federal Financial Supervisory Authority (BaFin), Bonn, with regard to compliance with the provisions of Sections 34b and 34c of the German Securities Trading Act (WpHG) as well as the German Regulation on Financial Analysis.

Supervisory Authority:

Federal Financial Supervisory Authority
Graurheindorfer Str. 108
53117 Bonn

Contact Montega:

Schauenburgerstraße 10
20095 Hamburg
www.montega.de / Tel: +49 40 4 1111 37 80

Statement pursuant to Section 85 WpHG and MAR as well as MiFID II, including Delegated Regulations (EU) No. 2016/958 and (EU) No. 2017/565

This publication has been prepared on the basis of a contractual agreement between Montega AG and the issuer and has been remunerated by the latter. This document has been broadly disseminated and made available to all interested parties simultaneously. Its receipt therefore constitutes a permissible minor non-monetary benefit within the meaning of Section 64 (7) sentence 2 no. 1 and 2 WpHG.

Key Valuation Principles and Methodologies Underlying the Investment Judgements Contained in this Document

The valuations underlying the investment judgements of Montega AG are based on generally accepted and widely used methods of fundamental analysis.

The fair value or price target of a share is primarily determined using the following methodologies:

Discounted Cash Flow (DCF) model: The DCF model applies projections of future free cash flows, which are discounted to determine their present value. As a rule, the weighted average cost of capital (WACC) is used as the discount rate in order to reflect the time value of money, the risks associated with the cash flows and the company's financing structure. The enterprise value is derived using the DCF analysis.

A sensitivity analysis of key underlying valuation parameters (WACC, growth rate, EBIT margin) is incorporated in the respective DCF models and illustrates the range of possible enterprise values per share resulting from variations in assumptions.

Peer group comparisons: A relative valuation approach used to derive enterprise value. The peer group generally comprises sufficiently comparable listed companies. Comparisons may be based on revenue, earnings metrics (e.g. EBITDA, EBIT, EPS) or other key performance indicators.

Historical multiples valuation (where applicable): A valuation method in which enterprise value is determined based on historical valuation multiples (e.g. EV/EBITDA, P/E ratio) of the company in relation to current or forecast financial metrics.

Sum-of-the-parts model (where applicable): A valuation approach deriving enterprise value from the aggregate value of individual assets. Equity value is determined by deducting net debt.

The outcome of this fundamental valuation may be adjusted to reflect the analyst's assessment of expected investor sentiment and its potential impact on the share price.

Irrespective of the valuation methodology applied, there is a risk that the price target may not be achieved. Key influencing factors may include, in particular, deviations of actual business performance from the assumptions underlying the valuation model, changes in capital market valuation levels (e.g. valuation multiples or discount rates), adjustments to risk premia, changes in financing conditions, regulatory interventions with direct effects on the business model, margins or capital structure, corporate actions, as well as lower market liquidity of the share.

Forward-looking statements, forecasts, estimates, price targets and scenarios are based on assumptions and expectations that may prove to be incorrect. Unexpected economic, regulatory or company-specific developments may result in actual outcomes differing materially from the assessments presented herein. Investments in foreign markets and instruments entail additional risks, in particular arising from exchange rate fluctuations as well as political and regulatory conditions.

This report reflects the opinion of the respective author at the time of its preparation. Subsequent changes in the fundamental factors underlying the valuation may lead to the assessment no longer being valid.

Past performance is not a reliable indicator of future results.

Meaning of the Investment Recommendation

The investment horizon for the following recommendations is generally twelve months, unless explicitly stated otherwise in the text.

Investment Recommendation	Expected Price Performance of the Financial Instrument (within 12 months)
Buy	The price of the analysed financial instrument is expected to increase.
Hold	The price of the analysed financial instrument is expected to remain broadly stable.
Sell	The price of the analysed financial instrument is expected to decline.
Recommendation suspended	The current information base does not allow for a well-founded assessment of the company.

Sources of Information and Updates

The information underlying this publication is derived from publicly available sources, company disclosures and discussions with company representatives, which Montega considered to be reliable at the time of preparation. However, no representation or warranty is made as to the accuracy, completeness or timeliness of the information used. No independent verification of all data has been carried out.

This publication is updated on an ad hoc basis when events occur that, in Montega's assessment, may be relevant to the share price. The timing and frequency of such updates are not determined in advance. Montega assumes no obligation to update, revise or adapt this publication to reflect changing market conditions.

Any discontinuation of regular coverage of events relating to the issuer (coverage) will be communicated in advance. Unless stated otherwise, price data refer to the closing price of the last trading day prior to publication of this analysis.

Statistical Distribution and History of Investment Recommendations

A tabular overview of individual investment recommendations over the past twelve months – including publication date, responsible analyst, respective price target, relevant market price at the time of publication and the corresponding recommendation – is available for the respective issuer via the following [overview page](#). The individual view also provides the statistical distribution of investment recommendations of Montega AG across the entire coverage universe.

Conflicts of interest

Montega has implemented various measures to avoid conflicts of interest. This includes a ban for all employees of Montega AG from trading stocks within the coverage universe for which Montega has a mandate for the creation of research. Additionally, both employees and the company are prohibited from accepting gifts from individuals with a special interest in the content of research publications. The remuneration of persons employed by or otherwise contractually engaged with Montega who are involved in the preparation of investment recommendations is not directly linked to transactions in investment services within the meaning of Annex I Sections A and B of Directive 2014/65/EU or to any other transactions carried out by Montega AG or any of its affiliated companies.

To ensure maximum transparency, Montega has created an overview in accordance with § 85 WpHG and Article 20 of Regulation (EU) No. 596/2014 in conjunction with Delegated Regulation 2016/958.

- (1) In the past 12 months, Montega AG has entered into an agreement with the issuer for the creation of financial analyses, for which Montega AG receives compensation.
- (2) In the past 12 months, Montega AG has entered into an agreement with a third party for the creation of financial analyses, for which Montega AG receives compensation.
- (3) In the past 12 months, Montega AG has provided other consulting services to this company and/or its shareholders.
- (4) In the last 12 months, Montega AG and/or a contractually bound affiliated entity have been party to an agreement with the analyzed company for services related to investment banking activities or have received compensation from such an agreement.
- (5) Montega AG and/or an affiliated entity expect compensation from the company for investment banking services in the next three months or intend to seek such compensation.
- (6) At the time of publication, Montega AG's analyst responsible for the publication or another Montega AG employee holds shares representing over 5% of the analyzed issuer's share capital.
- (7) At the time of publication, Montega AG's analyst responsible for the publication or another Montega AG employee holds a net long or short position of more than 0.5% of the analyzed issuer's share capital.
- (8) A company affiliated with Montega AG may be involved in the share capital of the issuer or hold other financial instruments in this company.
- (9) Montega AG or an affiliated entity has significant financial interests in the analyzed company, such as obtaining and/or exercising mandates or providing services for the analyzed company (e.g., roadshows, round tables, earnings calls, presentations at conferences, etc.).
- (10) In the last 12 months, Montega AG provided services (through a third party) to a member of the analyzed company's management related to the transfer of shares of the analyzed company and received compensation for this.
- (11) Montega AG has presented the issuer as an investment opportunity to a potential investor and is entitled to a remuneration from the potential investor if the latter invests in the issuer.
- (12) The issuer has commissioned Montega AG to provide additional services for which Montega AG is entitled to a remuneration from the issuer.

Company	Disclosure (as of 10.07.2026)
Alzchem Group AG	1, 5, 8, 9

This financial analysis was made available to the issuer prior to publication and was amended thereafter. The pre-disclosure takes place only after completion of the substantive analysis and serves to identify potential factual inaccuracies. Permissible feedback is limited to objectively verifiable information, in particular published financial data, dates, product designations, segment classifications or corporate structures. The investment recommendation and price target are not disclosed to the issuer prior to publication. Comments from the issuer regarding valuation models, assumptions, forecasts, peer group selection, investment case or risk assessment are acknowledged. However, the decision on any amendments rests exclusively with the responsible analyst. The issuer has no right of veto.

Price history

Recommendation	Date	Price (EUR)	Price target (EUR)	Potential
Buy (Initiation)	03.02.2025	64.60	82.00	+27%
Buy	03.03.2025	78.00	86.00	+10%
Hold	05.05.2025	121.00	105.00	-13%
Hold	24.07.2025	164.40	140.00	-15%
Hold	30.07.2025	146.00	140.00	-4%
Hold	04.11.2025	156.40	160.00	+2%
Buy	09.12.2025	154.80	175.00	+13%
Buy	10.02.2026	150.20	175.00	+17%
Buy	03.03.2026	154.80	175.00	+13%
Buy	14.04.2026	177.10	200.00	+13%
Buy	04.05.2026	165.90	200.00	+21%
Buy	10.07.2026	170.90	220.00	+29%